Biotechnology

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

The 2026 International Talents Conference highlights Hong Kong's aggressive strategy to attract global professionals and integrate with the Greater Bay Area.

A new high-resolution spatial biology service in Hong Kong is set to accelerate research in cancer and neuroscience across the Asia-Pacific region.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

Dr. Ginna Laport, a leader from both pharma and academia, joins NMDP to spearhead a new initiative aimed at making life-saving cell therapies a reality for more patients.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

CRB appoints veteran John R. Lupa, Jr. to spearhead national construction, a strategic move to dominate the booming life sciences and food facility market.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.